[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371872-105":59,"doc-detail-371872-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ppt1-is-a-negative-regulator-of-sting-signaling-in-cancer-cells-and-its-inhibition-reactivates-immune-surveillance-in-cold-tumors","PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors","","Immunologically “cold” tumors often lack T cell infiltration and do not respond well to immune checkpoint blockade. This work investigates how stimulator of interferon gene (STING) signaling can be therapeutically activated despite clinic failures of STING agonists caused by poor tumor penetrance and systemic toxicities. A genome-wide CRISPR screen identifies PPT1 as a lysosomal negative regulator of STING in cold ovarian and prostate cancers. PPT1 suppression increases STING stability and downstream interferon and inflammatory cytokine signaling, promoting CD8+ T cell migration and converting tumors to a “hot” phenotype while reducing growth, fibrosis, and dissemination without toxicity. Clinical correlations link PPT1 to reduced STING expression, CD8+ T cell numbers, survival, and immunotherapy outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ppt1-is-a-negative-regulator-of-sting-signaling-in-cancer-cells-and-its-inhibition-reactivates-immune-surveillance-in-cold-tumors/371872/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ppt1-is-a-negative-regulator-of-sting-signaling-in-cancer-cells-and-its-inhibition-reactivates-immune-surveillance-in-cold-tumors/371872.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does PPT1 play in STING signaling in cold tumors?","Question",{"text":112,"@type":113},"PPT1 acts as a negative regulator of STING, contributing to reduced STING signaling in cold ovarian and prostate tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does inhibiting PPT1 affect STING activity and immune response?",{"text":117,"@type":113},"Genetic or pharmacological PPT1 suppression increases STING protein stability, enhances downstream interferon and inflammatory cytokine signaling, and promotes T cell migration.",{"name":119,"@type":110,"acceptedAnswer":120},"What impact does PPT1 inhibition have on tumor behavior in preclinical models?",{"text":121,"@type":113},"In preclinical prostate and ovarian cancer models with low STING, PPT1 inhibition increases STING expression and activation, leading to cytotoxic T cell infiltration and activation, tumor growth reduction, and decreased fibrosis and dissemination without toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371872,1790802572,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","RESEARCH ARTICLE  \nIMMUNOLOGY AND INFLAMMATION  \nPPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors  \nShreya R. Chowdhurya, Chaitanya N. Parikha, Arshia N. Kaurb, Kelly D. DeMarcoa, Hadiya K. Giwaa, Alok K. Mishraa, Katherine C. Murphya, Lin Zhoua, Boyang Maa, Tianyi Yea, Junhui Lia, Haibo Liua, Shi Baic, Calvin Johnsond,e, Karl Simina, Jason R. Pitarresid,e, Lihua Julie Zhua,f,g , Emma V. Watsonb,  \nMichelle A. Kellihera , Michael R. Greena,1, Katherine A. Fitzgeralde,2, and Marcus Ruscettia,2 Affiliations are included on p. 11.  \nContributed by Katherine A. Fitzgerald; received June 10, 2025; accepted August 15, 2025; reviewed by Judy Lieberman and Jenny Ting  \nImmunotherapy modalities have revolutionized cancer treatment for a number of metastatic and treatment-refractory tumor types. Still, many malignancies that lack T cell infiltration and are termed immunologically “cold” fail to respond to these modalities. One approach to increase tumor immunogenicity has been to induce stimulator of interferon gene (STING) and downstream interferon signaling that is often dysregulated in cold tumors. Despite some early success of STING agonists in preclinical cancer models, these approaches have not been successful in the clinic due to poor tumor penetrance and systemic toxicities. Here, we performed a genome-wide CRISPR screen to uncover therapeutic targets to activate STING expression in human tumors. We identified the lysosomal hydrolase Palmitoyl Protein Thioesterase1 (PPT1) as a negative regulator of STING highly expressed in cold ovarian and prostate tumors. Genetic or pharmacological PPT1 suppression increased STING protein stability and its downstream activation of interferon and inflammatory cytokine signaling to enhance T cell migration. Treatment of preclinical prostate and ovarian cancer models expressing low levels of STING with the small molecule PPT1 inhibitor GNS561 enhanced STING expression and activation, leading to infiltration and activation of cytotoxic T cells that turned these tumors “hot” and reduced tumor growth, fibrosis, and dissemination without toxicity. Further analysis demonstrated that PPT1 is associated with reduced STING expression, CD8+ T cell numbers, overall survival, and immunotherapy outcomes in ovarian and prostate cancer patients. Thus, PPT1 inhibition maybe a promising approach to activate STING and potentiate the effects of immunotherapy in cold tumors.  \nSTING | cancer | inflammatory | Palmitoyl Protein Thioesterase 1  \nImmune checkpoint blockade (ICB) therapies against CTLA-4 and PD-1/PD-L1 designed to reactivate antitumor T cell immunity have shown remarkable results in many treatment-refractory solid tumors, and have become frontline regimens for non–small cell lung cancer and melanoma patients (1) . Still, only a subset of these patients respond to ICB, and other immunologically “cold” tumor types lacking robust cytotoxic lymphocyte infiltrates, antigen presentation, and PD-L1 expression generally fail to benefit (2) . In addition, many patients suffer from severe immune-related adverse events as a consequence of the systemic inflammatory effects of immunotherapy (3) . Innovative strategies and new therapy modalities are needed to elicit immune-mediated tumor control in a safe manner in the majority of cancer patients.  \nOne approach to make cold tumors “hot” and sensitized to immunotherapy has been the implementation of stimulator of interferon genes (STING) agonists (4) . STING is activated by intracellular cyclic dinucleotide (CDNs) such as the secondary messenger cGAMP produced via the cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS) (5) . This in turn leads to downstream interferon regulatory factor 3 (IRF3) and nuclear factor κB (NF-κB) transcription factor activity, culminating in Type I interferon (IFN) and proinflammatory cytokine production that can enhance antigen presentation and initiate antit","cbCaij4llI0Pq6Gx","https://ap.wps.com/l/cbCaij4llI0Pq6Gx","pdf",8714156,12,"English","# Significance\n## Immunotherapy challenges in cold tumors\n## STING activation and downstream pathways\n## PPT1 as a negative regulator and therapeutic inhibition results","[{\"question\":\"What role does PPT1 play in STING signaling in cold tumors?\",\"answer\":\"PPT1 acts as a negative regulator of STING, contributing to reduced STING signaling in cold ovarian and prostate tumors.\"},{\"question\":\"How does inhibiting PPT1 affect STING activity and immune response?\",\"answer\":\"Genetic or pharmacological PPT1 suppression increases STING protein stability, enhances downstream interferon and inflammatory cytokine signaling, and promotes T cell migration.\"},{\"question\":\"What impact does PPT1 inhibition have on tumor behavior in preclinical models?\",\"answer\":\"In preclinical prostate and ovarian cancer models with low STING, PPT1 inhibition increases STING expression and activation, leading to cytotoxic T cell infiltration and activation, tumor growth reduction, and decreased fibrosis and dissemination without toxicity.\"}]","PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors | PDF",1790193073,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42da1068afa6cf8c61e3c552580ae04b.webp",983,1316,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84ef359aaa57ae89f1625bab242e4cab.webp",982,1315,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2c15edee34e6758d184ec57dfbd5d17.webp",981,1313,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8050597c3c08d0a9875629bb5c5a857d.webp",980,1312]